BIIB
BIOGEN INC.
Nasdaq: BIIB · Cambridge, MA · Healthcare
$185.95+2.61 (+1.42%)Closed
Market Cap$27.30B
Cash$2.91Bmost recent
Runwayprofitable
P/E (TTM)21.2EPS $8.79
52-Wk Range$116.82 – $201.18
Avg Volume1.6M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$185.95-4.2%
Pipeline

Drug candidates sponsored by BIOGEN · ClinicalTrials.gov

66 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4rituximab
Non-Hodgkin's Lymphoma
Completed
2007-06past
1
Phase 4Interferon-beta-1a (Avonex) plus methylprednisolone
Relapsing-remitting Multiple Sclerosis
Completed
2008-11past
1
Phase 4Interferon-beta-1a
Relapsing-Remitting Multiple Sclerosis
Completed
2009-12past
2
Phase 4Methylprednisolone
Immune Reconstitution Inflammatory Syndrome+1 more
Terminated
2012-02past
1
Phase 4Fampridine
Multiple Sclerosis
Completed
2013-07past
1
Phase 4dimethyl fumarate
Relapsing-Remitting Multiple Sclerosis+4 more
Completed
2017-04-24past
5
Phase 4peginterferon beta-1a
Relapsing Remitting Multiple Sclerosis+2 more
Completed
2020-10-26past
3
Phase 4natalizumab
Relapsing-Remitting Multiple Sclerosis+5 more
Completed
2023-10-02past
8
Phase 4Tofersen
Amyotrophic Lateral Sclerosis+1 more
Recruiting
2027-08-07
3
Phase 4Interferon beta-1a
Relapsing Remitting Multiple Sclerosis
Completed—1
Phase 3BG00002 (natalizumab)
Multiple Sclerosis, Relapsing-Remitting+1 more
Completed
2009-12past
2
Phase 3BG00012
Relapsing-Remitting Multiple Sclerosis
Completed
2011-02past
1
Phase 3BIIB041 (Fampridine-SR)
Multiple Sclerosis
Completed
2012-06past
1
Phase 3BIIB019 (Daclizumab High Yield Process)
Relapsing-Remitting Multiple Sclerosis
Completed
2014-03past
2
Phase 3Placebo
Relapsing-Remitting Multiple Sclerosis+2 more
Completed
2020-11-11past
2
Phase 3BIIB111
Choroideremia
Completed
2020-12-01past
1
Phase 3SAGE-217
Major Depressive Disorder+4 more
Completed
2021-10-25past
3
Phase 3BIIB074
Trigeminal Neuralgia
Withdrawn
2025-10-14past
2
Phase 3Felzartamab
Antibody-mediated Rejection+2 more
Recruiting
2026-12-01
3
Phase 3BIIB017 (peginterferon beta-1a)
Multiple Sclerosis, Relapsing-Remitting
Active, not recruiting
2027-05-20
1
Phase 3Salanersen
Muscular Atrophy, Spinal
Recruiting
2028-11-28
2
Phase 3Diroximel Fumarate
Relapsing Forms of Multiple Sclerosis
Not yet recruiting
2034-07-28
1
Phase 1IDEC-114
Non-Hodgkin's Lymphoma
Completed
2002-09past
1
Phase 2BIIB014
Parkinson's Disease
Completed
2008-12past
1
Phase 2Lumiliximab + FCR
Chronic Lymphocytic Leukemia
Terminated
2010-06past
1
Phase 1mefloquine
Progressive Multifocal Leukoencephalopathy
Terminated
2010-11past
1
Phase 2BIIB033 (anti-LINGO-1 mAb)
Acute Optic Neuritis
Completed
2014-10past
1
Phase 2BIIB033
Multiple Sclerosis
Completed
2015-12past
1
Phase 2BIIB023
Lupus Nephritis
Terminated
2015-12past
1
Phase 2Bardoxolone methyl
Pulmonary Arterial Hypertension+13 more
Completed
2018-01-19past
2
Phase 2Nusinersen
Spinal Muscular Atrophy
Completed
2018-09-24past
2
Phase 2BIIB059 (litifilimab)
Systemic Lupus Erythematosus+1 more
Completed
2019-08-28past
1
Phase 2BIIB104
Cognitive Impairment Associated With Schizophrenia
Completed
2022-03-23past
1
Phase 2BIIB091
Relapsing Forms of Multiple Sclerosis+2 more
Completed
2026-02-10past
4
Phase 2RTA 402 Dose1
Malignant Melanoma
Withdrawn—1
Phase 1IDEC-152
Chronic Lymphocytic Leukemia
Completed
2004-04past
1
Phase 1hCBE-11
Tumors
Terminated
2006-08past
1
Phase 1BIIB017 (PEGylated Interferon Beta-1a)
Healthy
Completed
2008-05past
1
Phase 1CNF2024
Tumors+1 more
Completed
2008-07past
1
Phase 1Dimethyl Fumarate (BG00012)
Healthy
Completed
2011-03-18past
1
Phase 1BIIB022
Hepatocellular Carcinoma
Completed
2011-04past
1
Phase 1Experimental
Healthy Volunteers
Completed
2011-09past
1
Phase 1PF-04958242 capsule
Healthy
Completed
2012-09past
1
Phase 1Test product
Healthy Volunteers
Completed
2012-09past
1
Phase 1BIIB037
Alzheimer's Disease
Completed
2013-08past
1
Phase 1bismuth subsalicylate (Pepto-Bismol®)
Healthy
Completed
2013-12past
1
Phase 1dimethyl fumarate - Reference form
Healthy
Completed
2014-07past
1
Phase 1BIIB061
Healthy
Completed
2014-09past
1
Phase 1BIIB068
Systemic Lupos Erythematosus, SLE
Completed
2016-12past
1
Phase 1Aducanumab
Alzheimer's Disease
Completed
2016-12-09past
1
Phase 1Placebo oral capsule
Healthy
Completed
2019-06-28past
1
Phase 1BIIB076
Alzheimer's Disease+1 more
Completed
2020-03-03past
1
Phase 1BIIB054
Parkinson's Disease+1 more
Completed
2021-04-23past
2
Phase 1BIIB078
Amyotrophic Lateral Sclerosis
Terminated
2022-05-03past
1
Phase 1HIB210
Immune System Diseases+1 more
Completed
2024-06-10past
1
Phase 1BIIB122
Healthy Volunteer
Completed
2024-06-18past
1
Phase 1Omaveloxolone
Healthy Adult Subjects+1 more
Recruiting
2029-10-01
3
Phase 1CNF1010 (17-AAG)
Chronic Lymphocytic Leukemia
Terminated—1
N/AUnnamed
Multiple Sclerosis
Completed
2015-05past
1
N/ABenepali
Rheumatoid Arthritis+1 more
Completed
2018-11-30past
1
N/AUnnamed
Multiple Sclerosis
Completed
2020-04-30past
1
N/ATysabri
Progressive Multifocal Leukoencephalopathy
Completed
2023-12-31past
1
N/AUnnamed
Multiple Sclerosis, Relapsing-Remitting
Completed
2024-11-28past
1
N/AZuranolone
Depression, Postpartum+1 more
Recruiting
2026-08-24
2
N/AUnnamed
Muscular Atrophy, Spinal
Active, not recruiting
2027-09-02
1
N/AUnnamed
Multiple Sclerosis
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.